Activating Compound | Comment | Organism | Structure |
---|---|---|---|
cholesterol | 0.01 mM, isoform SphK2, 107% of initial activity | Homo sapiens | |
galactosylceramide | 0.01 mM, isoform SphK2, 84% of initial activity, isoform SphK1, 109% of initial activity | Homo sapiens | |
galactosylceramide 3-sulfate | 0.01 mM, isoform SphK2, 37% of initial activity, isoform SphK1, 156% of initial activity | Homo sapiens | |
phosphatidic acid | 0.01 mM, isoform SphK2, 102% of initial activity, isoform SphK1, 265% of initial activity | Homo sapiens | |
phosphatidylinositol | 0.01 mM, isoform SphK2,187% of initial activity | Homo sapiens | |
phosphatidylinositol 4-phosphate | 0.01 mM, isoform SphK2, 89% of initial activity, isoform SphK1, 175% of initial activity | Homo sapiens | |
phosphatidylserine | 0.01 mM, isoform SphK2, 203% of initial activity | Homo sapiens |
Cloned (Comment) | Organism |
---|---|
- |
Homo sapiens |
Protein Variants | Comment | Organism |
---|---|---|
additional information | isoform SphK2 contains a lipid binding domain at the N-terminal residues 1-175, a region of sequence that is absent in Sphk1. Deleting the N-terminal domain reduces Sphk2 membrane localisation in cells | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
3-O-sulfogalactosylceramide | endogenous glycolipid sulfatide, binds to and inhibits the activity of isoform Sphk2 and the closely related ceramide kinase Cerk, but not isoform Sphk1. The lipid binding domain is mapped to the N-terminus of Sphk2, residues 1-175, a region of sequence that is absent in Sphk1, but aligns with a pleckstrin homology domain in Cerk | Homo sapiens | |
galactosylceramide | 0.01 mM, isoform SphK2, 84% of initial activity, isoform SphK1, 109% of initial activity | Homo sapiens | |
galactosylceramide 3-sulphate | 0.01 mM, isoform SphK2, 37% of initial activity, isoform SphK1, 156% of initial activity | Homo sapiens | |
additional information | isoform Sphk2 binds to phosphatidylinositol monophosphates but not to abundant cellular phospholipids | Homo sapiens | |
phosphatidylinositol 4,5-bisphosphate | 0.01 mM, isoform SphK2, 60% of initial activity, isoform SphK1, 90% of initial activity | Homo sapiens | |
phosphatidylinositol 4-phosphate | 0.01 mM, isoform SphK2, 89% of initial activity, isoform SphK1, 175% of initial activity | Homo sapiens |
KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|
1 | - |
nitrobenzoxadiazole-labeled sphingosine | pH 7.4, 35°C, presence of 10 microM 3-O-sulfogalactosylceramide | Homo sapiens | |
1.7 | - |
nitrobenzoxadiazole-labeled sphingosine | pH 7.4, 35°C | Homo sapiens | |
1.7 | - |
nitrobenzoxadiazole-labeled sphingosine | pH 7.4, 35°C, presence of 25 microM 3-O-sulfogalactosylceramide | Homo sapiens | |
3.6 | - |
nitrobenzoxadiazole-labeled sphingosine | pH 7.4, 35°C, presence of 4 microM 3-O-sulfogalactosylceramide | Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
membrane | deleting the N-terminal domain with residues 1-175 reduces Sphk2 membrane localisation in cells | Homo sapiens | 16020 | - |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
ATP + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine | - |
Homo sapiens | ADP + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine 1-phosphate | - |
? |